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Talimogene laherparepvec (T-VEC) (Imlygic, Amgen) is 
the first oncolytic virus approved for use in therapy for 
metastatic melanoma. T-VEC provides a treatment op-
tion for patients with limited metastatic disease. T-VEC 
is a genetically modified, live, attenuated herpes simplex 
virus type 1 designed to replicate in tumour cells and 
promote an enhanced anti-tumour response (1) T-VEC is 
administered by injection into cutaneous, subcutaneous 
or nodal lesions, which are visible and/or palpable and/
or visualized by ultrasonography (2).
Other local management options have been used to 
control metastatic disease in stage IIIB, but almost all have 
shown only a local effect and rapid disease relapse (3, 4). 
With T-VEC, responses occurred in injected and unin-
jected lesions, including a greater than 50% decrease in 
size in 15% of uninjected visceral lesions. 
The appearance of vitiligo has been described as an 
adverse event after administration of immune checkpoint 
inhibitors (5, 6). It has been reported as a marker of activity 
of the drug and long-term results, inducing clinicians to 
use it as a predictor of drug response (7). A T-VEC phase 
II study has reported 85% adverse events, all of which 
were grade 1 or 2. The appearance of vitiligo has been 
described in 3 patients out of 50 (8), although no details 
regarding duration and appearance have been reported.
CASE REPORTS
We describe here the appearance of a vitiligo phenomenon in the 
context of T-VEC therapy. Both patients were enrolled in a clinical 
trial after progression (Amgen 20120325, Eudra 2013-005552-
15). This trial consists of the injection of T-VEC in subcutaneous 
nodules of melanoma. We performed the injection under ultraso-
nography. The patients had no active autoimmune disease or any 
history of such disease in the clinical records (those would be 
exclusion criteria for enrolment in the trial).
Patient 1. The first patient was a 47-year-old man who had had a 
nodular ulcerated 3.2-mm melanoma, BRAF mutated, excised 3 
years previously. The sentinel lymph node had a metastatic deposit 
of 2 mm maximum tumour diameter and the 9 lymph nodes excised 
at the complete lymph node dissection (CLND) were negative. Six 
months after surgery he noticed the appearance of a nodule close to 
the wide local excision scar (1 year after diagnosis of the primary 
tumour) followed by other 5 lesions on the same leg, which were 
confirmed to be cutaneous metastases. Radiological evaluation 
confirmed the absence of any other tumour deposit and he was 
enrolled in the trial 20120325, a total volume of 3.5 ml T-VEC at 
108 PFU/ml was administered in 4 lesions.
A total of 14 administrations every 3 weeks were needed to com-
pletely shrink the metastases and to achieve a complete response. 
He developed a flu-like reaction after each administration. Two 
months after the last drug administration, hypochromic maculae 
appeared in some of the treated lesions on his leg (Fig 1). The 
patient remains in complete remission at 20 months. The size of 
the vitiligo has been stable since its first appearance (Fig. 1B)
Patient 2. The second patient was a woman of 80 years, who 
had a BRAF wild-type melanoma, 1.87-mm Breslow thickness, 
excised from her right leg. Sentinel lymph node (SLN) biopsy 
was not carried out. Two and a half years after the first diagnosis 
she developed a lymph node metastasis in the groin and a meta-
stasis on the skin graft of the wide excision. She was submitted 
to isolated limb perfusion with melphalan and tumour necrosis 
factor (TNF)-α) with a complete response. This was maintained 
for 14 months, when a new lesion (histologically confirmed) 
appeared on the same leg and she was treated with 26 cycles of 
T-VEC every 3 weeks, starting with an initial dose of 3 ml with a 
complete response. She developed a flu-like reaction after every 
administration. Two months after the last administration, some 
hypochromic areas appeared on her face, neckline and dorsum of 
her hands (Fig. 2). Seen under a Wood’s lamp, they were well de-
limited and hypopigmented, suggestive of a vitiligo phenomenon. 
She remains in complete remission at 16 months. The vitiligo has 
been stable in size since its first appearance.
DISCUSSION
T-VEC was US Food and Drug Administration (FDA) 
approved for recurrent unresectable cutaneous and sub-
cutaneous melanoma in October 2015. In a recent phase 
IIIB study, adverse events occurred in 93% of patients, 
with the most common being fatigue, chills, and pyrexia; 
grade ≥ 3 adverse events occurred in 24% of the T-VEC-
treated group (9).
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Fig. 1. Case 1. (A) Well-defined hypochromic lesions with non-pigmented 
hairs on the pretibial area. Those lesions appeared at the sites of the 
previous melanoma metastases. (B) At 20 months from the complete 
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We have described here the appearance of an immuno-
logical reaction after successful treatment with T-VEC. 
Interestingly, the vitiligo appeared both at the injection 
sites and at distance, thus reflecting the activity of the 
oncolytic virus, not only on the local immune cells, but 
also inducing an immune reaction against melanocytes at 
a distance. Usually those phenomena are more common 
with systemic drugs, when a systemic immune reaction has 
been observed (10). The fact that a local treatment could 
potentially induce a distant reaction should be considered 
as a systemic effect of the injected drugs. 
Autoimmune phenomena have been described in un-
treated melanoma patients (11), but are more frequently 
observed in patients receiving immune checkpoint inhibi-
tors, (5, 6, 12), being related to response to therapy and to a 
better outcome (7). In the cases described, the vitiligo was 
stable at the end of follow-up and the patients were both 
disease free at 16 and 20 months from the achievement of 
complete response. Long-term responses associated with 
vitiligo have been reported in mouse models and human 
melanoma patients (13–15).
Currently, T-VEC combined with other immune 
checkpoint inhibitors is under study in several countries; 
it is also being evaluated as neoadjuvant therapy for 
melanoma. These drugs can induce a wide spectrum of 
adverse effects, especially in the skin, so knowing those 
related to T-VEC is a matter of importance in melanoma 
practice. Moreover, both patients who developed vitiligo 
are in complete response after T-VEC treatment. 
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Fig. 2. Case 2. (A) Induced vitiligo after 2 months from the achievement 
of a complete response of melanoma metastases with T-VEC treatment. 
(B) Induced vitiligo on the dorsum of the hand. (C) Distribution of the 
induced vitiligo on the neck/chest and on the typical localization around 
the mouth, as seen under Wood’s lamp.
